Evotec (NASDAQ:EVO) Shares Gap Up – Here’s Why

Evotec SE (NASDAQ:EVO)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $3.58, but opened at $3.77. Evotec shares last traded at $3.85, with a volume of 32,036 shares.

Evotec Trading Up 10.2 %

The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The firm’s 50-day simple moving average is $3.68 and its 200-day simple moving average is $4.07.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. DCF Advisers LLC raised its holdings in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after acquiring an additional 12,816 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Evotec in the fourth quarter worth approximately $27,000. Bank of America Corp DE grew its holdings in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the 4th quarter valued at $166,000. Finally, CSS LLC IL bought a new position in shares of Evotec during the 4th quarter worth $50,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.